• Molecular NameMethyprylon
  • SynonymDea No; 2575; Methprylon; Methyprolon; Methyprylon [INN]; Methyprylone [INN-French]; Methyprylonum [INN-Latin]; Metiprilon; Metiprilona [INN-Spanish]; Metiprilone
  • Weight183.251
  • Drugbank_IDDB01107
  • ACS_NO125-64-4
  • Show 3D model
  • LogP (experiment)0.78
  • LogP (predicted, AB/LogP v2.0)0.92
  • pka12.0
  • LogD (pH=7, predicted)0.92
  • Solubility (experiment)71.5 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)-1.43
  • LogSw (predicted, AB/LogsW2.0)25.57
  • Sw (mg/ml) (predicted, ACD/Labs)6.75
  • No.of HBond Donors1
  • No.of HBond Acceptors3
  • No.of Rotatable Bonds2
  • TPSA46.17
  • StatusFDA approved; US withdrawn
  • AdministrationN/A
  • PharmacologyThis medicine was used for treating insomnia, but is now rarely used as it has been replaced by newer drugs with fewer side effects, such as benzodiazepines.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein binding60.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmHepatic. Methyprylon is almost completely metabolized.
  • Half life6~16 h
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicitySymptoms of overdose include excitation and convulsions.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A